480 related articles for article (PubMed ID: 28221062)
1. Habituation of distress and craving during treatment as predictors of change in PTSD symptoms and substance use severity.
Badour CL; Flanagan JC; Gros DF; Killeen T; Pericot-Valverde I; Korte KJ; Allan NP; Back SE
J Consult Clin Psychol; 2017 Mar; 85(3):274-281. PubMed ID: 28221062
[TBL] [Abstract][Full Text] [Related]
2. Substance use disorders and PTSD: Examining substance use, PTSD symptoms, and dropout following imaginal exposure.
Jarnecke AM; Allan NP; Badour CL; Flanagan JC; Killeen TK; Back SE
Addict Behav; 2019 Mar; 90():35-39. PubMed ID: 30355535
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Prolonged Exposure on Substance Use in Patients With Posttraumatic Stress Disorder and Substance Use Disorders.
Peirce JM; Schacht RL; Brooner RK
J Trauma Stress; 2020 Aug; 33(4):465-476. PubMed ID: 32598569
[TBL] [Abstract][Full Text] [Related]
4. Concurrent treatment of substance use disorders and PTSD using prolonged exposure: A randomized clinical trial in military veterans.
Back SE; Killeen T; Badour CL; Flanagan JC; Allan NP; Ana ES; Lozano B; Korte KJ; Foa EB; Brady KT
Addict Behav; 2019 Mar; 90():369-377. PubMed ID: 30529244
[TBL] [Abstract][Full Text] [Related]
5. Between-session and within-session habituation in Prolonged Exposure Therapy for posttraumatic stress disorder: a hierarchical linear modeling approach.
Sripada RK; Rauch SA
J Anxiety Disord; 2015 Mar; 30():81-7. PubMed ID: 25613235
[TBL] [Abstract][Full Text] [Related]
6. Does Traumatic Brain Injury Attenuate the Exposure Therapy Process?
Ragsdale KA; Gramlich MA; Beidel DC; Neer SM; Kitsmiller EG; Morrison KI
Behav Ther; 2018 Jul; 49(4):617-630. PubMed ID: 29937262
[TBL] [Abstract][Full Text] [Related]
7. The impact of treatment condition and the lagged effects of PTSD symptom severity and alcohol use on changes in alcohol craving.
Kaczkurkin AN; Asnaani A; Alpert E; Foa EB
Behav Res Ther; 2016 Apr; 79():7-14. PubMed ID: 26905901
[TBL] [Abstract][Full Text] [Related]
8. Integrated Treatment of PTSD and Substance Use Disorders: Examination of Imaginal Exposure Length.
Mills AC; Badour CL; Korte KJ; Killeen TK; Henschel AV; Back SE
J Trauma Stress; 2017 Apr; 30(2):166-172. PubMed ID: 28329434
[TBL] [Abstract][Full Text] [Related]
9. Integrated, exposure-based treatment for PTSD and comorbid substance use disorders: Predictors of treatment dropout.
Szafranski DD; Snead A; Allan NP; Gros DF; Killeen T; Flanagan J; Pericot-Valverde I; Back SE
Addict Behav; 2017 Oct; 73():30-35. PubMed ID: 28460246
[TBL] [Abstract][Full Text] [Related]
10. Treatment of co-occurring posttraumatic stress disorder and substance use: Does order of onset influence outcomes?
Bountress KE; Badour C; Flanagan J; Gilmore AK; Back SE
Psychol Trauma; 2018 Nov; 10(6):662-665. PubMed ID: 28771018
[TBL] [Abstract][Full Text] [Related]
11. Trauma-focused exposure therapy for chronic posttraumatic stress disorder in alcohol and drug dependent patients: A randomized controlled trial.
Coffey SF; Schumacher JA; Nosen E; Littlefield AK; Henslee AM; Lappen A; Stasiewicz PR
Psychol Addict Behav; 2016 Nov; 30(7):778-790. PubMed ID: 27786516
[TBL] [Abstract][Full Text] [Related]
12. The influence of traumatic brain injury on treatment outcomes of Concurrent Treatment for PTSD and Substance Use Disorders Using Prolonged Exposure (COPE) in veterans.
Gros DF; Lancaster CL; Horner MD; Szafranski DD; Back SE
Compr Psychiatry; 2017 Oct; 78():48-53. PubMed ID: 28803041
[TBL] [Abstract][Full Text] [Related]
13. A cognitive processing therapy-based treatment program for veterans diagnosed with co-occurring posttraumatic stress disorder and substance use disorder: The relationship between trauma-related cognitions and outcomes of a 6-week treatment program.
Peck KR; Coffey SF; McGuire AP; Voluse AC; Connolly KM
J Anxiety Disord; 2018 Oct; 59():34-41. PubMed ID: 30248534
[TBL] [Abstract][Full Text] [Related]
14. Are 60-minute prolonged exposure sessions with 20-minute imaginal exposure to traumatic memories sufficient to successfully treat PTSD? A randomized noninferiority clinical trial.
Nacasch N; Huppert JD; Su YJ; Kivity Y; Dinshtein Y; Yeh R; Foa EB
Behav Ther; 2015 May; 46(3):328-41. PubMed ID: 25892169
[TBL] [Abstract][Full Text] [Related]
15. Increased Resilience is Associated with Positive Treatment Outcomes for Veterans with Comorbid PTSD and Substance Use Disorders.
McGuire AP; Mota NP; Sippel LM; Connolly KM; Lyons JA
J Dual Diagn; 2018; 14(3):181-186. PubMed ID: 29668364
[TBL] [Abstract][Full Text] [Related]
16. Temporal dynamics of symptom change among veterans receiving an integrated treatment for posttraumatic stress disorder and substance use disorders.
Badour CL; Flanagan JC; Allan NP; Gilmore AK; Gros DF; Killeen T; Korte KJ; Brown DG; Kolnogorova K; Back SE
J Trauma Stress; 2022 Apr; 35(2):546-558. PubMed ID: 34773928
[TBL] [Abstract][Full Text] [Related]
17. Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trial.
Mills KL; Teesson M; Back SE; Brady KT; Baker AL; Hopwood S; Sannibale C; Barrett EL; Merz S; Rosenfeld J; Ewer PL
JAMA; 2012 Aug; 308(7):690-9. PubMed ID: 22893166
[TBL] [Abstract][Full Text] [Related]
18. Veterans with PTSD and comorbid substance use disorders: Does single versus poly-substance use disorder affect treatment outcomes?
Jeffirs SM; Jarnecke AM; Flanagan JC; Killeen TK; Laffey TF; Back SE
Drug Alcohol Depend; 2019 Jun; 199():70-75. PubMed ID: 31009834
[TBL] [Abstract][Full Text] [Related]
19. Emotional Activation and Habituation During Imaginal Exposure for PTSD Among Women With Borderline Personality Disorder.
Harned MS; Ruork AK; Liu J; Tkachuck MA
J Trauma Stress; 2015 Jun; 28(3):253-7. PubMed ID: 26062135
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Exposure-Based Risk Reduction Through Family Therapy for Co-occurring Substance Use Problems and Posttraumatic Stress Disorder Symptoms Among Adolescents: A Randomized Clinical Trial.
Danielson CK; Adams Z; McCart MR; Chapman JE; Sheidow AJ; Walker J; Smalling A; de Arellano MA
JAMA Psychiatry; 2020 Jun; 77(6):574-586. PubMed ID: 32022827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
